Pediatric Drug-Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations

Area of Science:

• Pharmacology and Pharmaceutical Sciences
• Pediatric Drug Safety

Background:

• Hospitalized and chronically ill pediatric patients frequently receive multiple medications, increasing the risk of drug-drug interactions (DDIs).
• Dedicated DDI evaluations are standard in adults but rarely conducted in children due to ethical and logistical challenges.
• Adult DDI data is often extrapolated to pediatric populations, which may not accurately reflect the actual interaction magnitude.

Purpose of the Study:

• To review key considerations for evaluating drug-drug interactions (DDIs) in pediatric patients.
• To highlight the necessity of pediatric-specific DDI assessments, distinct from adult data.
• To emphasize the role of pharmacometric modeling in predicting pediatric DDIs.

Main Methods:

• Review article summarizing existing knowledge and challenges in pediatric DDI evaluation.
• Focus on pharmacometric approaches, including population pharmacokinetic (Pop-PK) and physiologically based pharmacokinetic (PBPK) modeling.
• Consideration of drug-specific, patient-specific (age, disease, obesity), and methodological factors impacting DDI magnitude.

Main Results:

• Pediatric DDI magnitude can differ significantly from adults due to age-dependent physiological changes affecting drug disposition and response.
• Extrapolation of adult DDI data to children may be unreliable.
• Pharmacometric models require careful adjustment for age-related physiological variations to accurately predict pediatric DDIs.

Conclusions:

• Accurate pediatric DDI assessment necessitates separate evaluations, acknowledging unique physiological and disease-related factors.
• Advanced modeling techniques are essential for predicting and managing DDIs in pediatric populations.
• Further research and robust methodologies are needed to ensure the safety of polypharmacy in children.